Belrose Pharma is dedicated to developing innovative therapeutics for disease states with high unmet medical needs using a powerful range of proprietary formulation technologies.
Belrose Pharma Inc. is a privately-held clinical-stage biopharmaceutical company focused on the development of new treatments for orphan diseases and other conditions with high unmet medical needs. Belrose Pharma currently has two Phase 2/3 clinical programs and two additional earlier stage candidates with the potential for accelerated approval based on an abbreviated approval pathway.
Belrose has assembled a world-class Management Team and Advisory Board. Each member of our management team draws on their experience to help advance Belrose’s clinical programs.
Belrose’s Clinical Assets include drug candidates across a number of therapeutic areas, leveraging its proprietary linker and formulation technologies and development experience. Belrose currently holds the rights to two Phase II products, and expects to initiate Phase I activities on two further development programs in 2015.
Belrose is deploying its proprietary “releasable linker” conjugation technology and other techniques to improve the clinical efficacy of both novel therapeutics and approved molecules that would benefit from improved PK profile, increased bioavailability and more convenient administration.